FLGT (Fulgent Genetics) Total Current Assets: $479.0 Mil (As of Mar. 2026)


FLGT Fulgent Genetics Inc FLGT
64 GF Score
Price $20.86
GF Value $24.05
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Fulgent Genetics Total Current Assets?

Fulgent Genetics FLGT +0.14% 64 Total Current Assets is $479.0 Mil as of Mar. 2026. GuruFocus rates FLGT with a GF Score™ of 64/100 and a GF Value™ of $24.05 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Fulgent Genetics's total current assets for the quarter that ended in Mar. 2026 was $479.0 Mil.

Fulgent Genetics  (NAS:FLGT) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Fulgent Genetics's Liquidation Value for the quarter that ended in Mar. 2026 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=276.302-112.215+0.75 * 69.277+0.5 * 12.056
=222.1

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fulgent Genetics Total Current Assets Related Terms

Fulgent Genetics Total Current Assets Historical Data

* Premium members only.

The historical data trend for Fulgent Genetics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fulgent Genetics Total Current Assets Chart

Fulgent Genetics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 611.96 627.87 507.85 353.57 550.49

Fulgent Genetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 416.78 428.73 507.37 550.49 479.04
FLGT
64GF Score
Fulgent Genetics Inc FLGT
Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fulgent Genetics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Fulgent Genetics's Total Current Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=336.077+91.61+10.604+112.199
=550.5

Fulgent Genetics's Total Current Assets for the quarter that ended in Mar. 2026 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=276.302+75.736+12.056+114.948
=479.0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of $479.0 Mil mean?
Fulgent Genetics (FLGT) has a Total Current Assets of $479.0 Mil as of Mar. 2026. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Fulgent Genetics and its competitors.
Is Fulgent Genetics' Total Current Assets too high?
Fulgent Genetics' current Total Current Assets is $479.0 Mil. Overall, Fulgent Genetics has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fulgent Genetics' Total Current Assets compare to MYGN and CSTL?
Fulgent Genetics' Total Current Assets of $479.0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Medical Diagnostics & Research company?
A good Total Current Assets depends on the Medical Diagnostics & Research industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Fulgent Genetics and its competitors. Fulgent Genetics's current Total Current Assets is $479.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulgent Genetics stock overvalued right now?
Based on GuruFocus' analysis, Fulgent Genetics (FLGT) is currently considered Modestly Undervalued. The stock's GF Value™ is $24.05, compared to a current price of $20.86 — trading 13.3% below its estimated fair value. The current Total Current Assets is $479.0 Mil. Fulgent Genetics' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Fulgent Genetics (FLGT), the current Total Current Assets is $479.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fulgent Genetics (FLGT) Overvalued in 2026?

Based on GuruFocus' analysis, Fulgent Genetics stock appears to be undervalued. The current stock price of $20.86 is trading 13.3% below its estimated GF Value™ of $24.05. GuruFocus considers Fulgent Genetics to be Modestly Undervalued.

Key valuation signals for FLGT:

  • Total Current Assets: $479.0 Mil
  • GF Value™: $24.05 vs. price of $20.86 (13.3% below fair value)
  • GF Score™: 64/100 with 4 warning signs

No single metric tells the full story. See the FLGT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fulgent Genetics Business Description

Other Exchanges FLGT:Mexico
Address 4399 Santa Anita Avenue, El Monte, CA, USA, 91731
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
64GF Score

Get the complete analysis for FLGT

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.86
Price
$24.05
GF Value